XML 21 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Financing Transactions - Additional Information (Detail) (USD $)
6 Months Ended 1 Months Ended 6 Months Ended
Jun. 30, 2012
Mar. 30, 2012
Dec. 31, 2011
Jun. 30, 2011
PharmAthene
Jun. 30, 2012
Percentage Over Libor
Jun. 30, 2012
Year One
Jun. 30, 2012
Year Two
Jun. 30, 2012
Year Three [Member]
Jun. 30, 2012
There After
Jun. 30, 2012
Term Loan
Mar. 30, 2012
Credit Facilities
Term Loan
Jun. 30, 2012
Senior Secured Credit Facility Term Loans
Jun. 30, 2012
Senior Secured Credit Facility Term Loans
Revolving Line Of Credit
Mar. 30, 2012
Senior Secured Credit Facility Term Loans
Revolving Line Of Credit
Line of Credit Facility [Line Items]                            
Senior secured debt facility $ 2,500,000                   $ 2,500,000      
Line of credit facility, maximum borrowing capacity                           5,000,000
Revolving line of credit used                           900,000
Percentage of withdrawal from revolving loan qualified billed                       85.00%    
Percentage of withdrawal from revolving loan qualified unbilled                       80.00%    
Available loan agreement to borrow                         100,000  
Fixed interest rate on term loan 10.14%                          
Variable interest rate 1.50%                          
Fixed portion of the variable rate         5.00%                  
Interest rate on revolving line of credit 6.50%                          
Term loan and line of credit, maturity date 2015-09                          
Term loan , payment terms Payments on the term loan are interest-only for the first 10 months, which may be extended to 12 months if certain conditions described in the Loan Agreement are met. Subsequently, the term loan will fully amortize over its remaining term.                          
Percentage of prepayment premium           3.00% 3.00% 2.00% 2.00%          
Percentage of final payment premium                   3.00%        
Warrants issued to purchase shares of common stock 46,584 46,584   371,423                    
Common stock at an exercise price $ 1.61                          
Fair value attributable to the warrant 69,876                          
Debt financing costs 216,000                          
Common Stock Share issued 48,345,984   48,236,172 1,857,143                    
Common Stock issued price       $ 3.50                    
Warrant exercise price   1.61   3.50                    
Gross proceeds from issuance of stock       6,500,000                    
Net Proceeds from issuance of stock       $ 5,800,000